Moreover, in determining the need for additional adjuvant systemic therapy, while the presence of residual disease suffices for the HER-2-positive and triple-negative breast cancer subgroups, accurate node staging becomes essential for considering the inclusion of chemotherapy or CDK4/6 inhibitors alongside endocrine therapy in the hormone-positive, HER-2-negative patient subgroup [7, 8]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.